1. Apoptosis
  2. TNF-alpha

Pomalidomide (Synonyms: CC-4047; CC4047; CC 4047)

Cat. No.: HY-10984 Purity: >98.0%
Data Sheet SDS Handling Instructions

Pomalidomide is a known inhibitor of TNF-α release in LPS stimulated human PBMC with IC50 of 13 nM.

For research use only. We do not sell to patients.
Pomalidomide Chemical Structure

Pomalidomide Chemical Structure

CAS No. : 19171-19-8

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $176 In-stock
1 g $160 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products

    Pomalidomide purchased from MCE. Usage Cited in: Gen Comp Endocrinol. 2015 Dec 30;228:1-8.

    TNFα significantly inhibits the mRNA and protein expression of GSK-3β, while POM significantly induces the mRNA and protein expression of GSK-3β (A). The mRNA and protein expression of β-catenin is significantly induced by TNFα, but significantly inhibited by POM (B). The protein expression of PPARγ and C/EBPα is significantly inhibited by TNFα, while significantly induced by POM treatment (C and D).

    Pomalidomide purchased from MCE. Usage Cited in: Nat Commun. 2017 May 22;8:15398.

    HEK293T cells are treated with 50 μg/mL Cycloheximide and increasing concentrations of Lenalidomide, Thalidomide or with DMSO, and cells are incubated for 6 h. ZFP91 and GAPDH levels are detected using anti-ZFP91 or anti-GAPDH immunoblotting.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    Pomalidomide is a known inhibitor of TNF-α release in LPS stimulated human PBMC with IC50 of 13 nM.

    IC50 & Target

    IC50: 13 nM (TNF-α, in PBMCs)[1]

    In Vitro

    Pomalidomide also inhibits Whole Blood TNF-α with IC50 of 25 nM[1]. Exposure of lymphoma cells to Pomalidomide (CC-4047) leads to 40% decrease in cell proliferation when compared with vehicle-treated controls. Pomalidomide inhibits by 40% the DNA synthesis of Raji cells (P=0.036)[2]. In both CD4+ and CD8+ cells, Pomalidomide (CC-4047) is the most potent IL-2-elevator, followed by CC-6032 and CC-5013. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10, and slightly more potent than CC-5013 at elevating IFN-γ[3].

    In Vivo

    The administration of Pomalidomide (CC-4047) for two consecutive days before mAb therapy enhances the antitumor activity of Rituximab and doubled the median survival of lymphoma-bearing mice. Statistically, significant differences are observed between animals treated with Rituximab versus Pomalidomide+Rituximab. The median survival time of animals treated with Pomalidomide and Rituximab is longer (median survival, 74 days; 95% CI, 70-78) than those treated with Rituximab monotherapy (median survival, 38 days; 95% CI, 26-50; log-rank test, P=0.002). The administration of CC-5013 or Pomalidomide for two consecutive days leads to a significant increase in the number of circulating NK cells as shown by flow cytometry analysis, in lymphoma-bearing SCID mice[2]. Following a 50 mg/kg PO administration of Pomalidomide (POM) to rats, unbound concentrations in blood reach a Cmax value of 1100±82 ng/mL at 4.6±2.4 hours, with a concomitant AUC(0-10) value of 6800±2000 ng•hr/mL. Unbound POM in the brain, however, has a Cmax value of 430±63 ng/mL at 4.1±1.5 hours and an AUC(0-10) value of 2700±740 ng•hr/mL, giving an unbound AUCbrain to AUCblood ratio of 0.39±0.03. These values are consistent with excellent blood-brain-barrier penetration. The results obtained in this study are consistent with those seen in a concurrent study looking at whole brain POM content following its oral administration to mice[4].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT00717522 Celgene Corporation|Celgene Soft Tissue Sarcoma August 2008 Phase 2
    NCT01324947 Celgene Corporation Multiple Myeloma March 2011 Phase 3
    NCT01177735 University of Arkansas|Celgene Corporation Multiple Myeloma October 2011 Phase 2
    NCT00770757 Washington University School of Medicine Graft vs Host Disease February 2009 Phase 2
    NCT00669578 Mayo Clinic|National Cancer Institute (NCI) Chronic Myeloproliferative Disorders|Secondary Myelofibrosis May 2008 Phase 1|Phase 2
    NCT01522547 Celgene Corporation|Celgene Anemia, Sickle Cell August 2007 Phase 1
    NCT01474330 Celgene Corporation Healthy August 2011 Phase 1
    NCT00946270 M.D. Anderson Cancer Center|Celgene Polycythemia Vera|Thrombocythemia July 2009 Phase 2
    NCT00482521 Case Comprehensive Cancer Center|National Cancer Institute (NCI) Unspecified Adult Solid Tumor, Protocol Specific March 2007 Phase 1
    NCT01198067 M.D. Anderson Cancer Center|Celgene Corporation Lymphoma|Myeloma October 2010 Phase 1
    NCT00540579 SCRI Development Innovations, LLC|Celgene Corporation Pancreatic Cancer November 2007 Phase 1|Phase 2
    NCT00463385 Celgene Corporation|Celgene Myelofibrosis With Myeloid Metaplasia|Myeloid Metaplasia|Myelofibrosis April 2007 Phase 2
    NCT01053949 University Hospital, Lille|Celgene Corporation Multiple Myeloma October 2009 Phase 2
    NCT02011113 Celgene Corporation Multiple Myeloma December 2013 Phase 2
    NCT01707407 Celgene Corporation|Celgene Pharmacology, Clinical|Healthy September 2012 Phase 1
    NCT01311687 Celgene Multiple Myeloma March 2011 Phase 3
    NCT02164955 Celgene Multiple Myeloma June 26, 2014
    NCT00537511 Celgene Corporation|Celgene Carcinoma, Small Cell February 2008 Phase 1|Phase 2
    NCT01178281 Celgene Primary Myelofibrosis September 2010 Phase 3
    NCT00072722 Celgene Corporation|Celgene Prostate Cancer September 2003 Phase 2
    NCT03113942 Kirby Institute High Grade Squamous Intra-epithelial Lesion (HSIL) May 2017 Phase 2
    NCT02045017 Celgene Corporation Multiple Myeloma May 2014 Phase 2
    NCT01734928 Celgene Multiple Myeloma January 7, 2013 Phase 3
    NCT00833833 Celgene Corporation Multiple Myeloma June 2008 Phase 1|Phase 2
    NCT00558896 Mayo Clinic|National Cancer Institute (NCI) Multiple Myeloma and Plasma Cell Neoplasm November 2007 Phase 2
    NCT02555839 Celgene Multiple Myeloma March 1, 2015
    NCT01979276 Weill Medical College of Cornell University|Celgene Corporation Multiple Myeloma November 2013 Phase 1|Phase 2
    NCT01559129 Celgene Scleroderma, Systemic|Sclerosis, Systemic|Systemic Scleroderma|Systemic Sclerosis August 9, 2012 Phase 2
    NCT01997840 Celgene Multiple Myeloma March 1, 2014 Phase 1|Phase 2
    NCT01319422 Yale University|Celgene Corporation Multiple Myeloma June 2011 Phase 2
    NCT01078974 Steven P. Treon, MD, PhD|Celgene Corporation|Dana-Farber Cancer Institute Waldenstrom's Macroglobulinemia May 2010 Phase 1
    NCT01497093 Celgene|Multiple Myeloma Research Consortium Multiple Myeloma February 15, 2012 Phase 1
    NCT01495598 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Kaposi Sarcoma|Sarcoma, Kaposi December 9, 2011 Phase 1|Phase 2
    NCT01541332 Oncotherapeutics|Celgene Corporation Multiple Myeloma February 2012 Phase 1|Phase 2
    NCT00949364 University of Ulm Myeloproliferative Neoplasms December 2009 Phase 2
    NCT01568294 Celgene Corporation|Celgene Multiple Myeloma April 2012 Phase 1
    NCT01946477 Celgene Multiple Myeloma May 29, 2014 Phase 2
    NCT02287558 The Cleveland Clinic Hereditary Hemorrhagic Telangiectasia|Idiopathic Vascular Ectasia November 2014 Phase 1
    NCT01644110 University of Ulm Primary Myelofibrosis|Secondary Myelofibrosis|PMF|SMF|Post-PV MF|Post-ET MF August 2013 Phase 1|Phase 2
    NCT01946152 M.D. Anderson Cancer Center|Celgene Myeloma March 2014 Phase 1|Phase 2
    NCT02415153 National Cancer Institute (NCI) Neurofibromatosis Type 1|Recurrent Central Nervous System Neoplasm|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm July 14, 2015 Phase 1
    NCT01712789 Celgene Multiple Myeloma November 6, 2012 Phase 3
    NCT01212952 Mayo Clinic|National Cancer Institute (NCI) Refractory Multiple Myeloma September 2011 Phase 1|Phase 2
    NCT02004275 Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Celgene Corporation|Millennium Pharmaceuticals, Inc. Multiple Myeloma in Relapse February 2014 Phase 1|Phase 2
    NCT02046915 University Hospital Tuebingen Relapsed or Refractory Multiple Myeloma April 2014 Phase 2
    NCT01665794 University of Chicago|National Cancer Institute (NCI)|Multiple Myeloma Research Foundation Multiple Myeloma August 2012 Phase 1|Phase 2
    NCT01835561 Celgene Corporation|Celgene Clinical Pharmacology, Healthy Volunteer Study March 2013 Phase 1
    NCT01754402 Cristina Gasparetto|Celgene|Duke University Multiple Myeloma January 2013 Phase 1|Phase 2
    NCT02289222 Ashraf Badros|Merck Sharp & Dohme Corp.|University of Maryland Multiple Myeloma December 2014 Phase 1|Phase 2
    NCT01986894 Celgene Corporation|Celgene Clinical Pharmacology, Healthy Volunteer Study October 2013 Phase 1
    NCT02158702 National University Hospital, Singapore|Celgene Multiple Myeloma|Relapse After Use of Lenalidomide and Bortezomib November 2014 Phase 2
    NCT02176213 Ajai Chari|Celgene Corporation|Icahn School of Medicine at Mount Sinai Multiple Myeloma in Relapse|Multiple Myeloma, Refractory June 2014 Phase 2
    NCT02576977 Merck Sharp & Dohme Corp. Multiple Myeloma October 19, 2015 Phase 3
    NCT02384083 PETHEMA Foundation|Array BioPharma|Celgene Corporation Multiple Myeloma September 2015 Phase 1|Phase 2
    NCT01722305 Mayo Clinic|National Cancer Institute (NCI) B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Central Nervous System Lymphoma|Intraocular Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Recurrent Adult Diffuse Large Cell Lymphoma|Retinal Lymphoma April 2013 Phase 1
    NCT02569320 Yvonne Efebera|Celgene|Ohio State University Comprehensive Cancer Center Recurrent Plasma Cell Myeloma May 2016 Phase 1
    NCT01745588 Memorial Sloan Kettering Cancer Center|Celgene Corporation|Weill Medical College of Cornell University|North Shore University Hospital|Rutgers Cancer Institute of New Jersey|State University of New York - Upstate Medical University Multiple Myeloma December 2012 Phase 2
    NCT01432600 H. Lee Moffitt Cancer Center and Research Institute|Celgene Myeloma November 2011 Phase 1|Phase 2
    NCT02902900 Celgene Corporation Multiple Myeloma September 2015
    NCT01807286 M.D. Anderson Cancer Center|Celgene Myeloma January 2014 Phase 1
    NCT01510613 IRCCS Policlinico S. Matteo Primary Amyloidosis of Light Chain Type February 2012 Phase 2
    NCT01159574 Weill Medical College of Cornell University|Celgene Multiple Myeloma August 2010 Phase 2
    NCT01464034 Academic Myeloma Consortium|Criterium, Inc.|Amgen|Celgene Corporation Multiple Myeloma November 2011 Phase 1|Phase 2
    NCT02103335 Triphase Research and Development I Corporation|Celgene Corporation Multiple Myeloma in Relapse|Refractory Multiple Myeloma|Multiple Myeloma June 5, 2014 Phase 1
    NCT01728259 Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) Light Chain Deposition Disease|Primary Systemic Amyloidosis March 2013 Phase 1
    NCT01745640 University Hospital, Lille|Celgene Corporation Multiple Myeloma January 2012 Phase 2
    NCT01632826 Celgene Multiple Myeloma
    NCT03143985 Case Comprehensive Cancer Center Multiple Myeloma July 2017 Phase 1
    NCT02119468 City of Hope Medical Center|National Cancer Institute (NCI) Refractory Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma June 30, 2014 Phase 1|Phase 2
    NCT01166113 Fondazione Neoplasie Sangue Onlus Multiple Myeloma July 2010 Phase 1|Phase 2
    NCT03151811 Oncopeptides AB Multiple Myeloma May 2017 Phase 3
    NCT02406222 University of Leeds|Myeloma UK|Celgene Multiple Myeloma March 2016 Phase 2
    NCT02542657 University of California, Davis|Takeda|Celgene Myeloma October 2015 Phase 1|Phase 2
    NCT02400242 Celgene Multiple Myeloma May 7, 2015 Phase 1
    NCT02189343 Celgene Multiple Myeloma September 15, 2014 Phase 1
    NCT01999335 Amgen Multiple Myeloma November 2013 Phase 1|Phase 2
    NCT02661022 Stemline Therapeutics, Inc. Multiple Myeloma January 2016 Phase 1|Phase 2
    NCT02244125 Institut Curie|Intergroupe Francophone du Myelome|Celgene Corporation Multiple Myeloma|First Relapse April 2014 Phase 2
    NCT01889420 New Mexico Cancer Care Alliance|Novartis Multiple Myeloma in Relapse July 2014 Phase 1
    NCT01794039 Mayo Clinic|National Cancer Institute (NCI) Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma March 2014 Phase 2
    NCT02659930 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Kaposi Sarcoma January 4, 2016 Phase 1
    NCT02075996 iOMEDICO AG Multiple Myeloma January 2014
    NCT03180736 European Myeloma Network|Janssen Research & Development, LLC Multiple Myeloma June 9, 2017 Phase 3
    NCT03143049 National University Hospital, Singapore|Celgene|International Myeloma Foundation (IMF) Relapse Multiple Myeloma June 1, 2017 Phase 3
    NCT02654132 Bristol-Myers Squibb|Celgene|AbbVie Multiple Myeloma March 16, 2016 Phase 2
    NCT02547662 Mayo Clinic|National Cancer Institute (NCI) Plasma Cell Leukemia|Plasma Cell Myeloma|Plasmacytoma December 2015 Phase 2
    NCT01135199 Stanford University|Celgene Corporation Pulmonary Fibrosis Phase 2
    NCT02168205 Celgene Corporation Healthy Volunteers May 2014 Phase 1
    NCT03030261 Washington University School of Medicine|Bristol-Myers Squibb|Celgene Multiple Myeloma in Relapse July 2017 Phase 2
    NCT02718833 Massachusetts General Hospital|Celgene|Bristol-Myers Squibb|Multiple Myeloma Research Consortium Multiple Myeloma June 2016 Phase 2
    NCT01570387 Vaishali Sanchorawala|Celgene Corporation|Boston Medical Center AL Amyloidosis June 2012 Phase 1|Phase 2
    NCT03170882 Millennium Pharmaceuticals, Inc.|Takeda Relapsed and/or Refractory Multiple Myeloma August 1, 2017 Phase 2|Phase 3
    NCT01575925 Celgene Multiple Myeloma|Renal Impairment June 1, 2012 Phase 1
    NCT02990338 Sanofi Plasma Cell Myeloma December 2016 Phase 3
    NCT02029950 National Cancer Institute (NCI) Acute Myeloid Leukemia|Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts 20 Percent or More of Bone Marrow Nucleated Cells|Blasts 5-19 Percent of Peripheral Blood White Cells|Chronic Myelomonocytic Leukemia-2|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Previously Treated Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia December 16, 2013 Phase 1
    NCT02228512 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma August 15, 2014 Phase 1|Phase 2
    NCT01688466 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Graft vs Host Disease|Graft-Versus-Host Disease August 29, 2012 Phase 2
    NCT03015922 University of Leeds|Myeloma UK|Oncolytics Biotech|Celgene Corporation Multiple Myeloma June 5, 2017 Phase 1
    NCT02283775 Sanofi Plasma Cell Myeloma May 2015 Phase 1
    NCT02916420 Jiangsu Simcere Pharmaceutical Co., Ltd. Multiple Myeloma September 2016 Phase 3
    NCT02578121 University of Arkansas Multiple Myeloma December 2015 Phase 2
    NCT02548962 Pharmacyclics LLC.|Celgene Corporation Multiple Myeloma March 2016 Phase 1|Phase 2
    NCT01522872 Threshold Pharmaceuticals Multiple Myeloma February 2012 Phase 1|Phase 2
    NCT02188368 Oncotherapeutics|Celgene Corporation Multiple Myeloma August 2014 Phase 2
    NCT01562405 Massachusetts General Hospital|Multiple Myeloma Research Consortium Multiple Myeloma May 2012 Phase 1
    NCT02726581 Bristol-Myers Squibb|AbbVie Multiple Myeloma April 21, 2016 Phase 3
    NCT02612779 Bristol-Myers Squibb Multiple Myeloma November 19, 2015 Phase 2
    NCT02939183 Amgen Relapsed or Refractory Multiple Myeloma January 17, 2017 Phase 1
    NCT02921828 Celgene Multiple Myeloma May 21, 2015
    NCT02616640 Celgene Multiple Myeloma January 11, 2016 Phase 1
    NCT02185820 Stichting Hemato-Oncologie voor Volwassenen Nederland|University of Turin, Italy Multiple Myeloma June 2014 Phase 1|Phase 2
    NCT03104270 Oncotherapeutics Multiple Myeloma March 13, 2017 Phase 2
    NCT02155634 Celgene Corporation|Celgene Multiple Myeloma|Neoplasms|Plasma Cells|Paraproteinemias|Blood Protein Disorders|Hematologic Diseases|Therapeutic Uses July 2014 Phase 3
    NCT01638936 Biotest Pharmaceuticals Corporation|Biotest Multiple Myeloma July 2012 Phase 1|Phase 2
    NCT02071888 Calithera Biosciences, Inc Non-Hodgkin's Lymphoma (NHL)|Multiple Myeloma|Waldenstrom's Macroglobulinemia (WM)|Diffuse Large B-cell Lymphoma (DLBCL),|Other B-cell NHL Subtypes, Including WM|T-cell NHL February 2014 Phase 1
    NCT01592370 Bristol-Myers Squibb Non-Hodgkin's Lymphoma|Hodgkin Lymphoma|Multiple Myeloma June 27, 2012 Phase 1
    NCT03023527 PETHEMA Foundation|Celgene|Bristol-Myers Squibb|Adknoma Health Research, S.L. Multiple Myeloma January 2017 Phase 1
    NCT01421186 MorphoSys AG Multiple Myeloma July 2011 Phase 1|Phase 2
    NCT02343042 Karyopharm Therapeutics Inc Multiple Myeloma October 2015 Phase 1|Phase 2
    NCT02963493 Oncopeptides AB|Precision Oncology Multiple Myeloma November 2016 Phase 2
    NCT02807454 Celgene Multiple Myeloma July 7, 2016 Phase 2
    NCT02462525 AbbVie Multiple Myeloma May 6, 2015 Phase 1
    NCT02626481 University Hospital, Lille|Janssen, LP|Intergroupe Francophone du Myelome Multiple Myeloma December 2015 Phase 2
    NCT02431208 Hoffmann-La Roche Multiple Myeloma July 22, 2015 Phase 1
    NCT02336815 Karyopharm Therapeutics Inc Multiple Myeloma May 2015 Phase 2
    NCT02998047 Baylor Research Institute|Actinium Pharmaceuticals Refractory Multiple Myeloma December 2016 Phase 1
    NCT01537861 Washington University School of Medicine Multiple Myeloma June 2012 Early Phase 1
    NCT02900716 Zhejiang DTRM Biopharma Chronic Lymphocytic Leukemia|B-Cell Lymphoma September 2016 Phase 1
    NCT02092922 Array BioPharma Advanced Multiple Myeloma May 2014 Phase 2
    NCT02265510 Incyte Corporation Advanced Cancer August 2014 Phase 1|Phase 2
    NCT03143036 National University Hospital, Singapore|Janssen, LP|International Myeloma Foundation (IMF) Relapse and / or Refractory Myeloma July 1, 2017 Phase 2
    NCT01998971 Janssen Research & Development, LLC Multiple Myeloma February 18, 2014 Phase 1
    NCT01243944 Incyte Corporation|Novartis Pharmaceuticals Polycythemia Vera October 2010 Phase 3
    NCT01421524 Celgene Multiple Myeloma|Lymphoma, Large B-Cell, Diffuse|Pleiotropic Pathway Modifier|Glioblastoma|Lymphoma|Primary Central Nervous System Lymphoma September 19, 2011 Phase 1
    View MoreCollapse
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 3.6598 mL 18.2989 mL 36.5979 mL
    5 mM 0.7320 mL 3.6598 mL 7.3196 mL
    10 mM 0.3660 mL 1.8299 mL 3.6598 mL
    Cell Assay

    Pomalidomide (CC-4047) is dissolved in DMSO (10 mg/mL) and stored, and then diluted with tissue culture media (DMSO <0.01%) before use[2].

    Lymphoma cell lines are placed in 96-well plates (1×105 cells per well) and exposed to escalating concentrations of CC-5013, Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL), or vehicle control single agents or in combination with Rituximab or Trastuzumab (isotype), at a final antibody concentration of 10 μg/mL. The final concentration is adjusted to 200 μL with 10% RPMI. The cell lines are incubated at 37°C and 5% CO2 for 24 and 48 hours. Following 24 or 48 hours, 1 μCi per well of [3H]-thymidine is added and cells are incubated for 18 hours more. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter. Each experiment is done in triplicate at three different times; results are presented as the mean of counts per minute (cpm) at 24 and 48 hours±SD[2].

    Animal Administration

    Pomalidomide (CC-4047) is dissolved in DMSO and diluted with saline or PBS before use (Mice)[2].
    Pomalidomide (CC-4047) is prepared in 0.5% carboxymethylcellulose/0.25% Tween 80 suspension (Rat)[4].

    Six- to 8-week-old SCID mice are used for this purpose. On day 0, all the animals receive 1×106 Raji cells via tail vein injection. After 72 hours of tumor engraftment, the animals are divided into seven cohorts. The first cohort (group A) serve as control and receive no treatment. Groups B and C consist of animals treated with either CC-5013 (0.5 mg/kg) or Pomalidomide (0.5 mg/kg) given i.p. on days +3, +4, +8, +9, +13, +14, +18, and +19. Groups D and E are treated with Rituximab or Trastuzumab (isotype control) monotherapy given via tail vein injection at 10 mg/kg on days +5, +10, +15, and +20. Finally, groups F and G consist of animals treated with Rituximab in combination with CC-5013 (group E) or Pomalidomide (group G). IMiDs are given i.p. for two consecutive days before each dose of Rituximab. After completion of therapy, animals are observed for a period of 90 days. The end point of the study is survival defined as the time for the development of limb paralysis. Animals that reach the end point or survived after 3 months of observation are sacrificed by cervical dislocation. Pathologic examination of all organs (liver, lung, and brain) is done to detect any residual disease. The experiments are repeated in three separate occasions.
    A total of 3 male CD-IGS rats are used. Pomalidomide is administered as a single PO administration via the stomach cannula, at 50 mg/kg (5 mL/kg) in a 0.5% carboxymethylcellulose/0.25% Tween 80 suspension formulation. Microdialysate is collected in a cooling fraction collector, set at 4°C at intervals of 25 minutes for 10 hours after dosing. To calculate AUC, the corrected concentration of each sample is multiplied by the interval over which the sample is collected; in this case 25 minutes, and divided by 60 minutes per hour. The sum of these values represented the total AUC value over the specified time range. To generate graphs, the concentration at each time point is plotted at the mid-point of each collection interval. Microdialysates are collected at the specified time points and analyzed for Pomalidomide concentration using a LC-MS/MS assay, within 12 hours.





    CAS No.


    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: